Protagenic Therapeutics, Inc.\new Investment Income, Interest
Protagenic Therapeutics, Inc.\new (PTIX) reported Investment Income, Interest of $8.10 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2025-05-13
- Protagenic Therapeutics, Inc.\new investment income, interest for the quarter ending 2025-03-31 was $8.10K, a 41.57% decline year-over-year.
- Protagenic Therapeutics, Inc.\new investment income, interest for the quarter ending 2024-12-31 was $9.03K, a 83.18% decline year-over-year.
- Protagenic Therapeutics, Inc.\new investment income, interest for the quarter ending 2024-09-30 was $11.28K, a 83.70% decline year-over-year.
- Protagenic Therapeutics, Inc.\new investment income, interest for the quarter ending 2024-06-30 was $9.29K, a 89.03% decline year-over-year.
- Protagenic Therapeutics, Inc.\new investment income, interest for fiscal 2024 was $43.47K, a 83.57% decline from fiscal 2023.
- Protagenic Therapeutics, Inc.\new investment income, interest for fiscal 2023 was $264.48K, a 42.35% increase from fiscal 2022.
- Protagenic Therapeutics, Inc.\new investment income, interest for fiscal 2022 was $185.79K, a 459.49% increase from fiscal 2021.
- Protagenic Therapeutics, Inc.\new investment income, interest for fiscal 2021 was $33.21K, a 6514.94% increase from fiscal 2020.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2025-03-31 | $8.10K 10-Q · filed 2025-05-13 | $17.13K derived: sum of 2 quarters · filed 2025-05-13 | $28.41K derived: sum of 3 quarters · filed 2025-05-13 | $37.70K derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | $9.03K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $20.31K derived: sum of 2 quarters · filed 2025-03-31 | $29.60K derived: sum of 3 quarters · filed 2025-03-31 | $43.47K 10-K · filed 2025-03-31 |
| 2024-09-30 | $11.28K 10-Q · filed 2024-11-14 | $20.57K derived: sum of 2 quarters · filed 2024-11-14 | $34.44K 10-Q · filed 2024-11-14 | $88.10K derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $9.29K 10-Q · filed 2024-08-14 | $23.16K 10-Q · filed 2024-08-14 | $76.81K derived: sum of 3 quarters · filed 2025-05-13 | $146.03K derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $13.87K 10-Q · filed 2025-05-13 | $67.52K derived: sum of 2 quarters · filed 2025-05-13 | $136.74K derived: sum of 3 quarters · filed 2025-05-13 | $221.45K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $53.66K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $122.88K derived: sum of 2 quarters · filed 2025-03-31 | $207.58K derived: sum of 3 quarters · filed 2025-03-31 | $264.48K 10-K · filed 2025-03-31 |
| 2023-09-30 | $69.22K 10-Q · filed 2024-11-14 | $153.93K derived: sum of 2 quarters · filed 2024-11-14 | $210.82K 10-Q · filed 2024-11-14 | $303.25K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $84.71K 10-Q · filed 2024-08-14 | $141.60K 10-Q · filed 2024-08-14 | $234.03K derived: sum of 3 quarters · filed 2024-08-14 | $276.52K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $56.89K 10-Q · filed 2024-05-15 | $149.32K derived: sum of 2 quarters · filed 2024-05-15 | $191.82K derived: sum of 3 quarters · filed 2024-05-15 | $224.72K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $92.43K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | $134.92K derived: sum of 2 quarters · filed 2024-05-14 | $167.82K derived: sum of 3 quarters · filed 2024-05-14 | $185.79K 10-K/A · filed 2024-05-14 |
| 2022-09-30 | $42.50K 10-Q · filed 2023-11-14 | $75.40K derived: sum of 2 quarters · filed 2023-11-14 | $93.36K 10-Q · filed 2023-11-14 | $126.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $32.90K 10-Q · filed 2023-08-14 | $50.87K 10-Q · filed 2023-08-14 | $83.51K derived: sum of 3 quarters · filed 2023-08-14 | $83.84K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $17.97K 10-Q · filed 2023-05-15 | $50.61K derived: sum of 2 quarters · filed 2023-05-15 | $50.94K derived: sum of 3 quarters · filed 2023-05-15 | $51.17K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $32.64K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $32.98K derived: sum of 2 quarters · filed 2023-03-31 | $33.20K derived: sum of 3 quarters · filed 2023-03-31 | $33.21K 10-K · filed 2023-03-31 |
| 2021-09-30 | $336.00 10-Q · filed 2022-11-14 | $563.00 derived: sum of 2 quarters · filed 2022-11-14 | $568.00 10-Q · filed 2022-11-14 | $576.00 derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $227.00 10-Q · filed 2022-08-11 | $232.00 10-Q · filed 2022-08-11 | $240.00 derived: sum of 3 quarters · filed 2022-08-11 | $257.00 derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $5.00 10-Q · filed 2022-05-13 | $13.00 derived: sum of 2 quarters · filed 2022-05-13 | $30.00 derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $8.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-07 | $25.00 derived: sum of 2 quarters · filed 2022-04-07 | $502.00 10-K · filed 2022-04-07 | |
| 2020-09-30 | $17.00 10-Q · filed 2021-11-15 | $494.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |